Sugammadex: a novel selective relaxant binding agent

References

• Läwen A. Über die Verbindung der Lokalanästhesie mit der Narkose, über hohe Extraduralanästhesie und epidurale Injektionen anästhesierender Lösungen bei tabischen Magenkrisen. Beitr. Klin. Chir.80, 168–180 (1912).
   Google Scholar
• Beecher HK, Todd DP. A study of deaths with anesthesia and surgery. Ann. Surg.140, 2 (1954).
   PubMed Web of Science ®Google Scholar
• Gild WM, Posner KL, Caplan RA, Cheney FW. Eye injuries associated with anesthesia. A closed claims analysis. Anesthesiology76(2), 204–208 (1992).
   PubMed Web of Science ®Google Scholar
• Domino KB, Posner KL, Caplan RA, Cheney FW. Awareness during anesthesia: a closed claims analysis. Anesthesiology90(4), 1053–1061 (1999).
   Google Scholar
• Viby-Mogensen J. Neuromuscular monitoring. In: Miller’s Anesthesia. Miller RD (Ed.). Elsevier–Churchill Livingstone, NY, USA (2005).
   Google Scholar
• Viby-Mogensen J, Jorgensen BC, Ording H. Residual curarization in the recovery room. Anesthesiology50(6), 539–541 (1979).
   PubMed Web of Science ®Google Scholar
• Debaene B, Plaud B, Dilly MP, Donati F. Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. Anesthesiology98(5), 1042–1048 (2003).
   PubMed Web of Science ®Google Scholar
• Murphy GS, Szokol JW, Marymont JH, Greenberg SB, Avram MJ, Vender JS. Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit. Anesth. Analg.107(1), 130–137 (2008).
   PubMed Web of Science ®Google Scholar
• Bartkowski RR. Incomplete reversal of pancuronium neuromuscular blockade by neostigmine, pyridostigmine, and edrophonium. Anesth. Analg.66(7), 594–598 (1987).
   Google Scholar
• Beemer GH, Bjorksten AR, Dawson PJ, Dawson RJ, Heenan PJ, Robertson BA. Determinants of the reversal time of competitive neuromuscular block by anticholinesterases. Br. J. Anaesth.66(4), 469–475 (1991).
   PubMed Web of Science ®Google Scholar
• Gwinnutt CL. Clinical Anaesthesia (2nd Edition). Blackwell Publishing Inc., Oxford, UK (2004).
   Google Scholar
• Naguib M, el-Gammal M, Daoud W, Ammar A, Moukhtar H, Turkistani A. Human plasma cholinesterase for antagonism of prolonged mivacurium-induced neuromuscular blockade. Anesthesiology82(5), 1288–1292 (1995).
   Google Scholar
• Belmont MR, Horochiwsky Z, Eliazo RF, Savarese JJ. Reversal of AV430A with cysteine in rhesus monkeys. Anesthesiology101 (2004) (Abstract A-1180).
   Google Scholar
• Bom A, Bradley M, Cameron K et al. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew. Chem. Int. Ed. Engl.41(2), 266–270 (2002).
   PubMed Web of Science ®Google Scholar
• Adam JM, Bennett DJ, Bom A et al. Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships. J. Med. Chem.45(9), 1806–1816 (2002).
   PubMed Web of Science ®Google Scholar
• Tarver GJ, Grove SJ, Buchanan K et al. 2-O-substituted cyclodextrins as reversal agents for the neuromuscular blocker rocuronium bromide. Bioorg. Med. Chem.10(6), 1819–1827 (2002).
   PubMedGoogle Scholar
• Cameron KS, Clark JK, Cooper A et al. Modified γ-cyclodextrins and their rocuronium complexes. Org. Lett.4(20), 3403–3406 (2002).
   Google Scholar
• Shields M, Giovannelli M, Mirakhur RK, Moppett I, Adams J, Hermens Y. Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block. Br. J. Anaesth.96(1), 36–43 (2006).
   PubMed Web of Science ®Google Scholar
• Sorgenfrei IF, Norrild K, Larsen PB et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology104(4), 667–674 (2006).
   PubMed Web of Science ®Google Scholar
• Naguib M. Sugammadex: another milestone in clinical neuromuscular pharmacology. Anesth. Analg.104(3), 575–581 (2007).
   PubMed Web of Science ®Google Scholar
• Epemolu O, Bom A, Hope F, Mason R. Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969. Anesthesiology99(3), 632–637 (2003).
   PubMed Web of Science ®Google Scholar
• Gijsenbergh F, Ramael S, Houwing N, van Iersel T. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology103(4), 695–703 (2005).
   PubMed Web of Science ®Google Scholar
• de Boer HD, van Egmond J, van de Pol F, Bom A, Booij LH. Chemical encapsulation of rocuronium by synthetic cyclodextrin derivatives: reversal of neuromuscular block in anaesthetized Rhesus monkeys. Br. J. Anaesth.96(2), 201–206 (2006).
   PubMedGoogle Scholar
• de Boer HD, van Egmond J, van de Pol F, Bom A, Booij LH. Reversal of profound rocuronium neuromuscular blockade by sugammadex in anesthetized rhesus monkeys. Anesthesiology104(4), 718–723 (2006).
   Google Scholar
• de Boer HD, van Egmond J, van de Pol F, Bom A, Booij LH. Sugammadex, a new reversal agent for neuromuscular block induced by rocuronium in the anaesthetized Rhesus monkey. Br. J. Anaesth.96(4), 473–479 (2006).
   PubMed Web of Science ®Google Scholar
• Naguib M. Sugammadex may replace best clinical practice: a misconception. Anesth. Analg.105(5), 1506–1507 (2007).
   Google Scholar
• Eleveld DJ, Kuizenga K, Proost JH, Wierda JM. A temporary decrease in twitch response during reversal of rocuronium-induced muscle relaxation with a small dose of sugammadex. Anesth. Analg.104(3), 582–584 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang MQ. Drug-specific cyclodextrins: the future of rapid neuromuscular block reversal? Drugs Future28, 347–354 (2003).
   Web of Science ®Google Scholar
• Proost JH, Eriksson LI, Mirakhur RK, Roest G, Wierda JM. Urinary, biliary and faecal excretion of rocuronium in humans. Br. J. Anaesth.85(5), 717–723 (2000).
   PubMed Web of Science ®Google Scholar
• Sparr HJ, Vermeyen KM, Beaufort AM et al. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. Anesthesiology106(5), 935–943 (2007).
   PubMed Web of Science ®Google Scholar
• Staals LM, Snoeck MM, Hunter JM, Heeringa M, Driessen JJ. Pharmacokinetics of rocuronium and sugammadex in patients with normal and impaired renal function. Presented at: 13th World Congress of Anesthetists (WCA). Cape Town, South Africa, 2–7 March 2008.
   Google Scholar
• Cammu G, De Kam PJ, Demeyer I et al. Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers. Br. J. Anaesth.100(3), 373–379 (2008).
   PubMed Web of Science ®Google Scholar
• de Kam P-J, van Kuijk J, Smeets J, Thomsen T, Peeters P. Single IV sugammadex doses up to 32 mg/kg are not associated with QT/QTc prolongation. Anesthesiology107 (2007) (Abstract A1580).
   Google Scholar
• de Kam P, van Kuijk J, Prohn M, Thomsen T, Peeters P. Single IV sugammadex doses up to 32 mg/kg alone or in combination with rocuronium or vecuronium are not associated with QTc prolongation. Eur. J. Anaesthesiol.25(Suppl.44) (2008) (Abstract AP5–9).
   Google Scholar
• Peeters P, Passier P, Smeets J, van Iersel T, Zwiers A. Single intravenous high-dose sugammadex (up to 96 mg/kg) is generally safe and well tolerated in healthy volunteers. Eur. J. Anaesthesiol.25(Suppl. 44), (2008).
   Google Scholar
• Decoopman M, Cammu G, Suy K, Heeringa M, Demeyer J. Reversal of pancuronium-induced block by the selective relaxant binding agent sugammadex. Eur. J. Anaesthesiol.24(Suppl. 39), 110–111 (2007).
   Google Scholar
• Suy K, Morias K, Cammu G et al. Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology106(2), 283–288 (2007).
   PubMed Web of Science ®Google Scholar
• Vanacker BF, Vermeyen KM, Struys MM et al. Reversal of rocuronium-induced neuromuscular block with the novel drug sugammadex is equally effective under maintenance anesthesia with propofol or sevoflurane. Anesth. Analg.104(3), 563–568 (2007).
   PubMed Web of Science ®Google Scholar
• Groudine SB, Soto R, Lien C, Drover D, Roberts K. A randomized, dose-finding, Phase II study of the selective relaxant binding drug, sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block. Anesth. Analg.104(3), 555–562 (2007).
   PubMed Web of Science ®Google Scholar
• de Boer HD, Driessen JJ, Marcus MA, Kerkkamp H, Heeringa M, Klimek M. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study. Anesthesiology107(2), 239–244 (2007).
   PubMed Web of Science ®Google Scholar
• Puhringer FK, Rex C, Sielenkamper AW et al. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, Phase II trial. Anesthesiology109(2), 188–197 (2008).
   PubMed Web of Science ®Google Scholar
• Flockton EA, Mastronardi P, Hunter JM et al. Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine. Br. J. Anaesth.100(5), 622–630 (2008).
   PubMed Web of Science ®Google Scholar
• Jones RK, Caldwell JE, Brull SJ, Soto RG. Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology109(5), 816–824 (2008).
   PubMed Web of Science ®Google Scholar
• Lee C, Jahr JS, Candiotti K, Warriner B, Zornow MH, Naguib M. Reversal of profound neuromuscular block by sugammadex administered 3 minutes after rocuronium: a comparison with spontaneous recovery from succinylcholine. Anesthesiology (In press).
   Google Scholar
• Staals LM, Snoeck MM, Driessen JJ, Flockton EA, Heeringa M, Hunter JM. Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function. Br. J. Anaesth.101, 492–497 (2008).
   PubMed Web of Science ®Google Scholar
• Sacan O, White PF, Tufanogullari B, Klein K. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine–glycopyrrolate and edrophonium–atropine. Anesth. Analg.104(3), 569–574 (2007).
   PubMed Web of Science ®Google Scholar
• Molina AL, de Boer HD, Klimek M, Heeringa M, Klein J. Reversal of rocuronium-induced (1.2 mg kg-1) profound neuromuscular block by accidental high dose of sugammadex (40 mg kg-1). Br. J. Anaesth.98(5), 624–627 (2007).
   PubMedGoogle Scholar
• Pühringer F, Blaszyk M, Cammu G, Sparr H, Heeringa M. Eur. J. Anaesthesiol.24(Suppl. 39), 111 (2007).
   Web of Science ®Google Scholar
• Duvaldestin P, Kuizenga K, Kjaer CC, Saldien V, Debaene B. Sugammadex achieves fast recovery from profound neuromuscular blockade induced by rocuronium or vecuronium: a dose–response study. Eur. J. Anaesthesiol.24(Suppl. 39), 123 (2007) (Abstract 129AP127–123).
   Google Scholar
• Blobner M, Eriksson L, Scholz J, Hillebrand H, Pompei L. Sugammadex (2.0 mg/kg) reverses shallow rocuronium-induced neuromuscular blockade significantly faster compared with neostigmine (50 µg/kg). Results from the AURORA trial. Eur. J. Anaesthesiol.24(Suppl. 39), 125 (2007) (Abstract 129AP127–110) .
   Web of Science ®Google Scholar
• Álvarez- Gómez JA, Wattwil M, Vanacker B, Lora-Tamayo JI, Khünl-Brady K. Reversal of vecuronium-induced shallow neuromuscular blockade is significantly faster with sugammadex compared with neostigmine. Results from the AURORA trial. Eur. J. Anaesthesiol.24(Suppl. 39) 124 (2007) (Abstract 9AP7–8).
   Google Scholar
• McDonagh D, Benedict PE, Kovac AL, Drover D, Brister NW. Efficacy and safety of sugammadex for reversal of rocuronium-induced blockade in elderly patients Anesthesiology107 (2007) (Abstract A1583).
   Google Scholar
• Plaud B, Meretoja O, Pohl B, Mirakhur RK, Raft J. The selective relaxant binding agent sugammadex is effective and safe for the reversal of rocuronium-induced neuromuscular blockade in paediatric and adult patients Eur. J. Anaesthesiol.24(Suppl. 39), 124 (2007) (Abstract 129AP127–125).
   Google Scholar
• Amao R, Zornow MH, McTaggart CR, Cheng DCH, Allard M. Sugammadex safely reverses rocuronium-induced blockade in patients with pulmonary disease. Anesthesiology107 (2007) (Abstract A1582).
   Google Scholar
• Dahl V, Pendeville PE, Hollman MW, Heier T, Blobner M. Reversal of rocuronium-induced neuromuscular blockade by sugammadex in cardiac patients Anesthesiology107 (2007) (Abstract A1581).
   Google Scholar
• Lemmens HJM, El-Orbany MI, Berry J, Martin G. Sugammadex reverses profound vecuronium blockade more rapidly than neostigmine Anesthesiology107 (2007) (Abstract A1578).
   Google Scholar
• Pavlin EG, White PF, Viegas OJ, Minkowitz HS, Hudson ME. Sugammadex given at least 15 min after rocuronium is effective in reversing neuromuscular blockade Anesthesiology107 (2007) (Abstract A1579).
   Google Scholar
• Wagner S, Pühringer FK, Spies C, Scholz J, Heeringa M, Wulf H. Sugammadex reverses neuromuscular blockade after continuous infusion of rocuronium in patients under sevoflurane or propofol maintenance anesthesia. Anesth. Analg.106(Suppl. 1), S218 (2008).
   Google Scholar